中国104家医院早期HER2阳性乳腺癌双靶新辅助治疗后辅助治疗现状调查报告(CSBrS-030)
A questionnaire on the status of adjuvant therapy after dual HER2-targeted neoadjuvant therapy for patients with early-stage HER2-positive breast cancer from 104 hospitals in China(CSBrS-030)
周思成 1辛灵 1江泽飞 2刘荫华 1中国临床肿瘤学会乳腺癌专业委员会 中华医学会外科学分会乳腺外科学组
作者信息
- 1. 北京大学第一医院甲状腺乳腺外科,北京 100034
- 2. 中国人民解放军第五医学中心肿瘤内科,北京 100039
- 折叠
摘要
目的 调查中国早期HER2阳性乳腺癌病人接受曲妥珠单抗+帕妥珠单抗联合细胞毒药物(简称"双靶")方案新辅助治疗后辅助治疗现状.方法 采用问卷调查方式登记了 2023-01-01-2023-12-31中国104家医院经治的Ⅰ～Ⅲ期乳腺癌病例,调查内容包括收治例数、HER2阳性乳腺癌占比、HER2阳性乳腺癌接受双靶方案新辅助治疗例数、新辅助治疗病理疗效评价方法及结果、双靶新辅助治疗后辅助治疗方案选择情况.结果 全国104家医院提供了 75 530例早期乳腺癌病人的临床病理资料.其中,7063例HER2阳性乳腺癌病人接受双靶方案新辅助治疗,4217例(59.7％)病人获得病理完全缓解(pCR),2846例未获得pCR(non-pCR).双靶新辅助治疗后,5658例(80.1％)沿用双靶辅助治疗,360例(5.1％)仅接受曲妥珠单抗辅助治疗,1045例(14.8％)病人接受其他药物.辅助靶向治疗方案选择与ypTNM分期间差异有统计学意义(x2=1730.058,P＜0.001).结论 ypTNM分期可能是HER2阳性乳腺癌双靶新辅助治疗后non-pCR病人制定后续辅助治疗方案的依据.
Abstract
Objective To investigate the status of adjuvant therapy in patients with early-stage human epidermal growth factor receptor 2(HER2)positive breast cancer in China after dual HER2-targeted neoadjuvant therapy,trastuzumab plus pertuzumab,combined with cytotoxic drugs.Methods The cases of stage Ⅰ-Ⅲ breast cancer treated at 104 hospitals in China between January 1,2023 and December 31,2023 were inquired by a questionnaire survey.The investigation included the number of cases,the proportion of HER2-positive breast cancer,the number of cases of HER2-positive breast cancer receiving dual HER2-targeted neoadjuvant therapy,the evaluation method and results of pathological response after neoadjuvant therapy,and adjuvant therapeutic regimen after neoadjuvant therapy.Results A total of 104 hospitals participated in the questionnaire and provided clinicopathological data of 75 530 patients with early-stage breast cancer,and 7063 patients(40.4％)with HER2-positive breast cancer received neoadjuvant therapy with a dual HER2-targeted regimen.4217 patients(59.7％)achieved pathologic complete response(pCR).The other 2846 patients did not achieved pCR(non-pCR).After dual HER2-targeted neoadjuvant therapy,5658 patients(80.1％)continued dual HER2-targeted adjuvant therapy,360 patients(5.1％)received trastuzumab adjuvant therapy,and 1045 patients(14.8％)received other drugs.There was significant difference between adjuvant targeted therapy in different ypTNM group(x2=1730.058,P＜0.00 1).Conclusion ypTNM stage can provide a basis for formulating follow-up adjuvant therapy regimen for HER2-positive breast cancer patients with non-pCR after dual HER2-targeted neoadjuvant therapy.
关键词
乳腺癌/人类表皮生长因子受体2阳性/新辅助治疗/双靶治疗/辅助治疗Key words
breast cancer/human epidermal growth factor receptor 2 positive/neoadjuvant therapy/dual-targeted therapy/adjuvant therapy引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据